Description:

GOG-0262: Solid Tumor Evaluation Form (D2M version 3) Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=6E6221CA-7BE9-32FA-E040-BB89AD43071B

Link:

https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=6E6221CA-7BE9-32FA-E040-BB89AD43071B

Keywords:
Versions (2) ▾
  1. 12/18/14
  2. 1/9/15
Uploaded on:

January 9, 2015

DOI:
No DOI assigned. To request one please log in.
License:
Creative Commons BY-NC 3.0 Legacy
Model comments:

You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.

Itemgroup comments for:

Item comments for:

In order to download data models you must be logged in. Please log in or register for free.

Fallopian Tube Cancer NCT01167712 On-Study - GOG-0262: Solid Tumor Evaluation Form (D2M version 3) - 2918350v1.0

No Instruction available.

  1. StudyEvent: GOG-0262: Solid Tumor Evaluation Form (D2M version 3)
    1. No Instruction available.
Header Module
Target Lesion(s) Evaluation
Did the patient have measurable disease at baseline
Lymph node
Method of Evaluation (*)
cm
cm
Non-target Lesion(s) Evaluation
Were there any non-target lesions reported at baseline
Method of Evaluation (*)
Follow-up status of lesion
New Target Lesion(s) At Follow-up Evaluation
Was the appearance of any new lesions documented (If no, skip to the Overall Response section below.)
Method of Evaluation (*)
Overall Response
Time point response (If q1=N and q8=N)
Time point response (If q1=N and q8=N)
Time point response (If q1=N and q8=N)
Overall best response
Overall best confirmed response
Comments

Similar models